AC Immune (ACIU) Financials: History & Chart

AC Immune S.A.(ACIU)

Biotechnology · Lausanne, VD

$2.52-0.19 (-6.92%)

Delayed quote: Oct 6, 2026, 12:25 PM EDT

About AC Immune S.A.

AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.

Lausanne, VD

106 employees

www.acimmune.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Martin Zügel

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	21.70M	18.70M	1.40M	426K	1.18M	1.65M	1.12M	1.25M	30.07M
Cost of Goods Sold	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	21.70M	18.70M	1.40M	426K	1.18M	1.65M	1.12M	1.25M	30.07M
Gross Profit Margin	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Total Operating Expenses	77.20M	17.22M	19.90M	18.60M	21.48M	26.08M	23.00M	21.75M	21.50M
Research & Development	57.36M	12.96M	14.69M	13.30M	16.41M	21.21M	17.98M	17.38M	17.09M
Selling, General & Administrative	13.76M	4.38M	5.22M	-320K	4.48M	4.91M	5.02M	-2.03M	4.43M
Operating Income (EBIT)	-55.50M	1.48M	-18.50M	-18.17M	-20.30M	-24.44M	-21.88M	-20.50M	8.58M
Operating Margin	-255.7%	7.9%	-1321.5%	-4262.1%	-1721.6%	-1484.5%	-1956.6%	-1637.5%	28.5%
Income Before Tax (EBT)	-54.24M	2.32M	-18.52M	-18.13M	-19.91M	-26.71M	-21.50M	-17.39M	6.49M
Interest Income	1.34M	212K	285K	442K	402K	577K	776K	979K	1.11M
Interest Expense	209K	75K	81K	53K	N/A	63K	61K	33K	39K
Other Income/Expense	1.25M	842K	-16K	42K	387K	-2.27M	385K	3.11M	-2.08M
Net Income	-54.24M	2.32M	-18.52M	-18.13M	-19.91M	-26.71M	-21.50M	-17.39M	6.49M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3K	0.00
Net Profit Margin	-249.9%	12.4%	-1322.7%	-4252.4%	-1688.8%	-1622.4%	-1922.1%	-1389.4%	21.6%
EBITDA	-54.25M	1.48M	-18.50M	-17.35M	-19.87M	-23.65M	-21.19M	-19.92M	9.20M
EBITDA Margin	-250.0%	7.9%	-1321.5%	-4069.8%	-1685.4%	-1436.8%	-1894.7%	-1590.9%	30.6%
Depreciation & Amortization	1.25M	0.00	0.00	820K	427K	785K	691K	582K	624K
EPS Basic	-0.54	0.02	-0.19	-0.18	-0.20	-0.26	-0.21	-0.17	0.07
EPS Diluted	-0.54	0.02	-0.19	-0.18	-0.20	-0.26	-0.21	-0.17	0.06
Weighted Average Basic Shares	98.67M	98.67M	98.67M	101.17M	99.11M	100.63M	100.41M	100.86M	99.84M
Weighted Average Diluted Shares	98.67M	98.67M	98.67M	101.17M	99.11M	100.63M	100.41M	100.86M	100.86M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	4.51M	30.07M	17.58M	4.26M	0.00	17.43M	114.02M	7.30M
Cost of Goods Sold	0.00	68.89M	64.86M	0.00	0.00	67.20M	52.06M	44.94M
Gross Profit	4.51M	-38.83M	-47.28M	4.26M	0.00	-49.77M	61.96M	-37.64M
Gross Profit Margin	100.0%	-129.1%	-268.9%	100.0%	N/A	-285.5%	54.3%	-515.5%
Total Operating Expenses	91.37M	18.85M	16.41M	80.87M	86.60M	19.43M	15.99M	57.59M
Research & Development	71.19M	68.89M	64.86M	65.25M	68.27M	67.20M	52.06M	44.94M
Selling, General & Administrative	14.70M	12.59M	12.56M	10.36M	11.92M	20.96M	16.58M	7.68M
Operating Income (EBIT)	-86.86M	-57.67M	-63.69M	-76.61M	-86.60M	-69.20M	45.97M	-50.29M
Operating Margin	-1927.3%	-191.8%	-362.3%	-1800.4%	N/A	-397.0%	40.3%	-688.8%
Income Before Tax (EBT)	-88.86M	-56.06M	-64.40M	-76.50M	-80.01M	-69.95M	46.91M	-51.71M
Interest Income	2.35M	3.52M	1.24M	75K	7.11M	88K	313K	129K
Interest Expense	241K	146K	209K	384K	637K	208K	1.99M	339K
Other Income/Expense	-2.00M	1.61M	-711K	116K	6.60M	-747K	935K	-1.42M
Net Income	-88.86M	-56.06M	-64.41M	-76.51M	-80.01M	-69.95M	46.91M	-51.71M
Income Tax Expense	0.00	3K	12K	14K	3K	0.00	0.00	0.00
Net Profit Margin	-1971.6%	-186.4%	-366.4%	-1798.0%	N/A	-401.3%	41.1%	-708.2%
EBITDA	-83.71M	-55.29M	-61.06M	-74.06M	-83.97M	-67.47M	47.29M	-49.31M
EBITDA Margin	-1857.3%	-183.9%	-347.3%	-1740.5%	N/A	-387.0%	41.5%	-675.4%
Depreciation & Amortization	3.16M	2.38M	2.63M	2.55M	2.64M	1.73M	1.32M	975K
EPS Basic	-0.88	-0.56	-0.76	-0.92	-1.06	-0.97	0.66	-0.83
EPS Diluted	-0.88	-0.56	-0.76	-0.92	-1.06	-0.97	0.66	-0.83
Weighted Average Basic Shares	100.75M	99.69M	84.69M	83.55M	74.95M	71.90M	70.60M	61.84M
Weighted Average Diluted Shares	100.75M	99.69M	84.69M	83.55M	74.95M	71.90M	71.10M	61.84M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.